Prescribing Information

ALECENSA®▼(alectinib)

Avastin® (bevacizumab)

Esbriet® (pirfenidone)

GAZYVARO® (obinutuzumab)

HEMLIBRA®▼(emicizumab)

Herceptin® (trastuzumab) IV

Herceptin® (trastuzumab) SC

Kadcyla®(trastuzumab emtansine)

OCREVUS®▼(ocrelizumab) [Great Britain]

OCREVUS®▼(ocrelizumab) [Northern Ireland]

Perjeta® (pertuzumab)

PHESGO®▼ (pertuzumab/trastuzumab)

Polivy®▼ (polatuzumab vedotin)

RoACTEMRA®(tocilizumab) RA/GCA

RoACTEMRA® (tocilizumab) pJIA/sJIA

RoACTEMRA® (tocilizumab) CRS

Rozlytrek®▼(entrectinib)

TECENTRIQ®▼ (atezolizumab) 1200mg - Hepatocellular Carcinoma [Great Britain]

TECENTRIQ®▼ (atezolizumab) 1200mg - Hepatocellular Carcinoma [Northern Ireland] 

TECENTRIQ®▼ (atezolizumab) 1200mg - Lung Cancer [Great Britain]

TECENTRIQ®▼ (atezolizumab) 840mg - Lung Cancer [Great Britain]

TECENTRIQ®▼ (atezolizumab) 1200mg - Lung Cancer [Northern Ireland] 

TECENTRIQ®▼ (atezolizumab) 840mg - Lung Cancer [Northern Ireland]

TECENTRIQ®▼ (atezolizumab) 840mg - Triple Negative Breast Cancer [Great Britain]

TECENTRIQ®▼ (atezolizumab) 840mg - Triple Negative Breast Cancer [Northern Ireland]

TECENTRIQ®▼ (atezolizumab) 1200mg - Urothelial Carcinoma [Great Britain] 

TECENTRIQ®▼ (atezolizumab) 840mg - Urothelial Carcinoma [Great Britain] 

TECENTRIQ®▼ (atezolizumab) 1200mg - Urothelial Carcinoma [Northern Ireland] 

TECENTRIQ®▼ (atezolizumab) 840mg - Urothelial Carcinoma [Northern Ireland]  

 

GCA, giant cell arteritis; GPA, granulomatosis with polyangiitis; HCC Hepatocellular carcinoma; IV, intravenous; mTNBC, metastatic triple-negative breast cancer;
MPA, microscopic polyangiitis; NSCLC, Non-small-cell lung carcinoma; pJIA, polyarticular juvenile idiopathic arthritis; RA, rheumatoid arthritis; SC, subcutaneous; sJIA, systemic juvenile idiopathic arthritis; UC, urothelial carcinoma;

For the Summary of Product Characteristics for all Roche products available in the UK please see www.medicines.org.uk/emc.

 

M-GB-00003319

Date of preparation: April 2021